Document is current
Any future updates will be listed below
-
Authors
Sherry, Alexander D. https://orcid.org/0000-0001-5115-1691
Msaouel, Pavlos https://orcid.org/0000-0001-6505-8308
Miller, Avital M.
Lin, Timothy A.
Kupferman, Gabrielle S.
Abi Jaoude, Joseph
Kouzy, Ramez
El-Alam, Molly B.
Patel, Roshal https://orcid.org/0000-0002-6117-5520
Koong, Alex
Lin, Christine
Meirson, Tomer
McCaw, Zachary R. https://orcid.org/0000-0002-2006-9828
Ludmir, Ethan B. https://orcid.org/0000-0002-5472-5344
-
Funding
Funding for this research was provided by:
Andrew Sabin Family Foundation
- License Information
-
More Information
Article History
Received: 30 April 2025
Revised: 11 July 2025
Accepted: 4 August 2025
First Online: 11 August 2025
Competing interests
: Dr. Sherry reports honoraria from Sermo. Dr. Msaouel reports honoraria for scientific advisory board membership for Mirati Therapeutics, Bristol-Myers Squibb, and Exelixis; consulting fees from Axiom Healthcare; non-branded educational programs supported by Exelixis, Pfizer, and DAVA oncology; leadership or fiduciary roles as a Medical Steering Committee Member for the Kidney Cancer Association and a Kidney Cancer Scientific Advisory Board Member for KCCure; and research funding from Takeda, Bristol-Myers Squibb, Mirati Therapeutics, and Gateway for Cancer Research (all unrelated to this manuscript’s content). Dr. Meirson reports consulting fees from Purple Biotech. Dr. McCaw reports employment at Insitro (unrelated to this manuscript’s content). No other authors report any conflicts of interest.
: A portion of this study was presented at the American Society of Clinical Oncology Annual Meeting on May 31, 2025 in Chicago, IL.
: All methods were performed in accordance with relevant guidelines and regulations. This study did not require IRB approval or participant informed consent as all study data were publicly available prior to study initiation in accordance with national guidelines.
